INTRODUCTION
Purulent conjunctivitis is common in childhood and is a source of concern for parents and physicians. The etiology is bacterial (generally Haemophilus in{luenzae or Streptococcus pneumoniae) in approximately 50% of cases. 1 Antimicrobial therapy enhances the eradication of these organisms from the conjunctivae and shortens the duration of the clinical disease. 2 The role of Staphylococcus aureus in nontraumatic conjunctivitis remains controversia1. 1, 3 This study compared the clinical and bacteriologic responses to a new Accepted for publication March 2, 1988 . Reprints not available.
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ophthalmic antimicrobial preparation, trimethoprimpolymyxin B (TP) , with the responses to gentamicin sulfate (GS) and sodium sulfacetamide (SS) in the treatment of bacterial conjunctivitis.
MATERIALS AND METHODS
Pharmacologic agents used. Trimethoprim hemisulfate, 1.0 mg/ml, and polymyxin B, 10 000 units/ml (Polytrim®; Burroughs-Wellcome Company), gentamicin sulfate, 3.0 mg/ml (Garamycin®; Schering Corporation) and sulfacetamide sodium, 100 mg/ml (Sodium Sulamyd®; Schering Corporation) were the ophthalmic solutions used. The antimicrobial agents chosen for comparison with trimethoprim-polymyxin B were selected because of a similar spectrum of in vitro antibacterial activity,4 solution formulation and common use.
Population. Patients between the ages of 2 months and 22 years of either sex and any race who at the time of an acute illness visit were diagnosed as having conjunctivitis were eligible for admission to the study. Patients were recruited for study at two sites: University of Virginia Children's Medical Center, Charlottesville, V A; and University of California-San Francisco, San Francisco, CA.
Study entry. The clinical diagnosis of conjunctivitis was based on at least three of the following criteria (adapted from Jarudi et a1.
5 ): ocular symptoms (e.g. itching, burning, photophobia or foreign body sensation); yellowish discharge or mattering; a polymorphonuclear neutrophilic response on Giemsa-or Gram-stained scraping ofthe conjunctiva; an environmental history of close exposure to bacterial conjunctivitis; or a history of inadequately treated bacterial conjunctivitis. The clinical diagnosis had to be confirmed with a laboratory diagnosis of bacterial infection.
Written informed consent to participate in the study was obtained. A careful history and eye examination were performed. The severity of 21 signs and 8 symptoms were graded and recorded (see "Clinical evaluation").
Patients were excluded from enrollment in the study Medication. Patients were assigned to receive either TP, GS or SS ophthalmic solutions according to a double blinded randomization schedule. Neither the patients nor the investigators were aware of which of the similarly bottled and similar appearing drugs the patients were receiving. One drop of medication was administered to the affected eye(s) every 3 hours, while the patient was awake, for 10 days (5 to 6 applications/day) .
Follow-up. Patients returned for a first follow-up 3 to 6 days after starting treatment and a final followup 2 to 7 days after completion of therapy. Signs and symptoms were evaluated at each follow-up visit; a repeat eye culture was obtained at the final visit. Compliance was assessed on the basis of a medication administration log completed by the patient or guardian.
Clinical evaluation. At each visit the investigator rated the presence and severity of 8 symptoms (itching, burning, foreign body sensation, photophobia, grittiness, watery discharge, purulent discharge, eyelids "stuck together" in the morning) and 21 signs (eyelid: edema, erythema, tenderness; eyelid margin: scales, erythema, ulcerations, meibomitis; palpebral conjunctiva: erythema, chemosis, papules, membrane, conjunctival hemorrhage; bulbar conjunctiva: diffuse or angular hyperemia; cornea: infiltrate, ulcer, keratitis (punctate), edema, filaments; tear film cells; and iritis).
Each factor was rated on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). An average severity index (ASI) was calculated for each patient by dividing the sum of these individual sign and symptom scores by the number of items scored. Many patients were rated on the full battery of 29 signs and symptoms; however, some patients, especially young children with whom an investigator was unable to communicate verbally, were rated on fewer symptoms.
Microbiologic evaluation. At the initial and final visits, an eye swab specimen for culture was obtained with a calcium alginate applicator by swabbing over the lower palpebral conjunctiva of each affected eye. The swab was immediately rolled on the surface of a 5% sheep's blood agar plate and a chocolate agar plate and processed according to standard bacteriologic methods. The plates were examined 24 and 48 hours later for growth of bacterial pathogens. Isolated organisms were identified according to standard methods.
Statistical analysis. The ASIs among patients in the three treatment groups at the follow-up visits were compared using a general linear models procedure. Three pairs of comparisons were made: TP us. GS; TP us. SS; and GS us. SS. These multiple comparisons required that we adjust the "significant" value of alpha downward using the Bonferroni procedure 6 such that p = 0.0167.
At the follow-up visits patients with an ASI of zero (i.e. no signs or symptoms) were considered "cured." Patients whose ASI had decreased to a value <50% of the pretreatment value were considered "improved." Patients whose ASI was ~50% to 100% of the pretreatment value were considered "unchanged." Patients whose ASI was >100% of the pretreatment value were considered "worse." Patients whose conjunctivitis was "worse" at the first follow-up visit were dropped from their treatment group and were considered "failures" in the final follow-up clinical analysis, although final bacteriologic cultures were not obtained. Patients who were "unchanged" or "worse" at the final follow-up visit were considered "failures" in the final follow-up analysis.
A case was considered evaluable for evidence of drug efficacy ifthe patient complied with the correct dosage regimen (fewer than 20 doses missed), if the eye cultures were obtained and processed correctly and if the clinical outcome could be strictly classified as "cured," "improved" or "failed." In the case of bilateral disease one eye was randomly selected for analysis via a computer-generated random schedule.
RESULTS
Three hundred thirty-seven patients qualified for enrollment in the study (Table 1) . One hundred thirtytwo (39%) of these patients were dropped from the study before the first follow-up because of no bacterial growth (79 patients) or growth of organisms other than H. in{luenzae or S. pneumoniae on initial culture (53 patients).
The remaining 205 patients were culture-positive for H. in{luenzae, S. pneumoniae or both. Forty-seven of the 205 patients (23%) could not be considered in the final analysis because they were lost to follow-up (28 patients), had inadequate medication administration (medication stopped, medication lost or 2::20 doses missed) (10 patients) or received a concomitant antibacterial medication (9 patients). The one patient with an adverse experience and the one patient who was a therapeutic failure at the first follow-up were dropped from their treatment groups but were included in the 158 patients considered in the final analysis. Mild lid edema, unassociated with other evidence of drug toxiCity, was considered an adverse experience in the one TOPICAL ANTIMICROBIALS FOR CONJUNCTIVITIS September, 1988 patient even though it was present before medication use. The patient considered to be a therapeutic failure was clinically worse but had no evidence of drug toxicity.
The mean severity index for each ofthe three groups at each of the clinical evaluations is reported in Table  2 . No significant differences existed among the groups for anyone visit.
The patients in the three study groups were comparable as to age, gender, race and pathogen (Table   3 ).
Clinical and bacteriologic responses by treatment groups are shown in Table 4 . At the first follow-upclinical cure or improvement was seen in 92, 95, and 89% of the patients treated with TP, GS and SS, respectively. At the final follow-up, the number of patients clinically cured, improved or failed was not statistically different for the three treatment groups (P > 0.1 by Fisher's exact test). Of the patient's considered clinical failures, all were unchanged; none was worse and none had an adverse experience. In addition no patient experienced spread from unilateral to bilateral disease.
The overall bacteriologic response was not statistically different for the three treatment groups (83, 68, and 72% for TP, GS and SS, respectively) (P > 0.1 by Fisher's exact test). However, the bacteriologic cure rate for H. influenzae infections appeared different for TP (81%) us. GS (57%) (P = 0.03) and for TP (81%) us. SS (57%) (P = 0.06).
DISCUSSION
Purulent conjunctivitis in children customarily has been treated with topical antibiotics. However, the effectiveness of such therapy was not studied in a controlled manner until Gigliotti et a1. 2 o Cured = ASI (see text) of zero; improved -ASI of <50% of the pretreatment value; unchanged = ASI of 2:50% to 100% of the pretreatment value; Worse s ASI of >100% of the pretreatment value; adverse experience = suspected drug toxicity.
examined 102
b Numbers in parentheses, percent. C Patients "worse" at first follow-up (1) or having an adverse experience (1) were dropped from their treatment groups and could not be evaluated bacteriologically at the final follow-up, children with purulent conjunctivitis in a randomized, double-blind trial of polymyxin-bacitracin us. placebo treatment. Gigliotti et al.
l had previously demonstrated that H. in{luenzae and S. pneumoniae were the only bacterial agents statistically associated with conjunctivitis in children older than 2 to 3 months of age. Therefore in their therapy trial, clinical and bacteriologic cure rates were determined for the 66 patients who had purulent conjunctivitis and isolation of H. in{luenzae, S. pneumoniae or both and who received only topical therapy_ Those treated with polymyxinbacitracin achieved significantly higher clinical cure rates by Days 3 to 5 than did those patients treated with placebo. The clinical cure rates at Days 8 to 10 were not significantly different. The bacterial pathogen was eradicated by medication in 71% of the patients at Days 3 to 5 and in 79% at Days 8 to 10; the pathogen was recovered in 81 % at Days 3 to 5 and remained present at Days 8 to 10 in almost 70% of the placebo-treated patients. The authors concluded that acute bacterial conjunctivitis is a self-limited disease, but topical antibiotic therapy with polymyxinbacitracin shortens the duration of the clinical disease and enhances eradication of the causative organism from the conjunctiva. 2 In our study clinical and bacteriologic responses to a new ophthalmic solution formulation of trimethoprim and polymyxin were compared with the responses to solutions containing either gentamicin sulfate or sodium sulfacetamide. All three preparations are known to have adequate in uitro activity against H. in{luenzae and S . pneumoniae. 4 Each of the three ophthalmic formulations was associated with high rates of clinical improvement or cure after 3 to 6 days oftherapy (92% for TP, 95% for G8 and 89% for 88). These clinical responses to topical antimicrobial therapy are consistent with those in the controlled study by Gigliotti et al. 2 The overall bacteriologic responses with the three medications were not statistically different and were also consistent with those obtained in the study by Gigliotti et al. 2 However, in our study eradication of H. in{luenzae at the final follow-up appeared better for TP (81 %) than for G8 (57%) (P = 0.03) or 88 (57%) (P = 0.06). The clinical significance of these findings was not apparent.
All test agents showed similar safety profiles with only one adverse experience reported in a patient who received TP therapy. It is questionable that the moderate lid edema present in this patient was related to therapy, since the condition was present before TP was started.
Ophthalmic formulations for treating acute conjunctivitis are selected by considering clinical efficacy, bacteriologic cure rates, adverse experiences, cost and ease of administration. The ophthalmic solution containing trimethoprim and polymyxin B hastens clinical cure, provides early eradication of the responsible bacterial organism and is associated with limited adverse experiences. It is a reasonable addition to the list of effective topical ophthalmic antimicrobials.
